Acquired familial Mediterranean fever associated with a somatic MEFV mutation in a patient with JAK2 associated post-polycythemia myelofibrosis

Orphanet J Rare Dis. 2015 Jun 30:10:86. doi: 10.1186/s13023-015-0298-6.

Abstract

Background: A study was designed to identify the source of fever in a patient with post-polycythemia myelofibrosis, associated with clonal Janus Kinase 2 (JAK2) mutation involving duplication of exon 12. The patient presented with 1-2 day long self-limited periodic episodes of high fever that became more frequent as the hematologic disease progressed.

Methods: After ruling out other causes for recurrent fever, analysis of the pyrin encoding Mediterranean fever gene (MEFV) was carried out by Sanger sequencing in peripheral blood DNA samples obtained 4 years apart, in buccal cells, laser dissected kidney tubular cells, and FACS-sorted CD3-positive or depleted mononucleated blood cells. Hematopoeitc cells results were validated by targeted deep sequencing. A Sanger sequence based screen for pathogenic variants of the autoinflammatory genes NLRP3, TNFRSF1A and MVK was also performed.

Results: A rare, c.1955G>A, p.Arg652His MEFV gene variant was identified at negligible levels in an early peripheral blood DNA sample, but affected 46 % of the MEFV alleles and was restricted to JAK2-positive, polymorphonuclear and CD3-depleted mononunuclear DNA samples obtained 4 years later, when the patient experienced fever bouts. The patient was also heterozygous for the germ line, non-pathogenic NLRP3 gene variant, p.Q705K. Upon the administration of colchicine, the gold standard treatment for familial Mediterranean fever (FMF), the fever attacks subsided.

Conclusions: This is the first report of non-transmitted, acquired FMF, associated with a JAK2 driven clonal expansion of a somatic MEFV exon 10 mutation. The non-pathogenic germ line NLRP3 p.Q705K mutation possibly played a modifier role on the disease phenotype.

Publication types

  • Case Reports

MeSH terms

  • Biopsy
  • Clone Cells
  • Colchicine / therapeutic use
  • Cytoskeletal Proteins / genetics*
  • Exons / genetics
  • Familial Mediterranean Fever / diagnosis
  • Familial Mediterranean Fever / drug therapy
  • Familial Mediterranean Fever / genetics*
  • Female
  • Gout Suppressants / therapeutic use
  • Humans
  • Janus Kinase 2 / genetics*
  • Middle Aged
  • Mutation*
  • Polycythemia Vera / diagnosis
  • Polycythemia Vera / drug therapy
  • Polycythemia Vera / genetics*
  • Polymorphism, Restriction Fragment Length
  • Primary Myelofibrosis / diagnosis
  • Primary Myelofibrosis / drug therapy
  • Primary Myelofibrosis / genetics*
  • Pyrin

Substances

  • Cytoskeletal Proteins
  • Gout Suppressants
  • MEFV protein, human
  • Pyrin
  • JAK2 protein, human
  • Janus Kinase 2
  • Colchicine